



Figure S5. ADI-PEG20 efficacy in an extended panel of ovarian cancer cell lines. Cells were treated with 0.63 µg/mL ADI-PEG20. First row represents ASS1 expressing cell lines, whereas the rest of the cells are ASS1 deficient, therefore sensitive to ADI-PEG20 treatment. OVCAR3: HGSC cell line; JHOC 9, OVTOKO: CCOC cell lines. BIN67, SCCOHT1: SCCOHT cell lines; OVISE and ES2 represent atypical CCOC/ENOC based on molecular characterizations; TOV112D: de-differentiated ovarian cancer cell line. Error bars represent standard error of mean.